Context Therapeutics Inc (CNTX NASDAQ) stock market data APIs
$2.4614
-0.14(-5.7%)
as of May 5, 2026
Try our APIs with
free plan!
Context Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company's product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. It has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
Prev. Close
2.4614
Open
2.3248
High
2.4625
Low
2.3237
52 wk Range
0.49-3.62
Market Cap
224 M
Shares Outstanding
91 879 K
EPS
-0.14
Beta
1.571
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Context Therapeutics Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Context Therapeutics Inc data using free add-ons & libraries
Get Context Therapeutics Inc Fundamental Data
Context Therapeutics Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -39 686 380
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get Context Therapeutics Inc Earnings data
Corporate Events Calendar & News package for
$
19.99
/mo.
What’s included:
- Latest Release: 2026-03-25
- EPS/Forecast: -0.1025
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Context Therapeutics Inc News
New
Context Therapeutics rises on FDA fast track status for lead asset
[US Food and Drug Administration (FDA)] Context Therapeutics (CNTX [https://seekingalpha.com/symbol/CNTX]) added ~11% on Thursday after the cancer drug developer said that the U.S. Food and Drug Admi...
Context Therapeutics Gains FDA Fast Track Status For CTIM-76 In Ovarian Cancer
(RTTNews) - Context Therapeutics Inc. (CNTX) on Thursday said the U.S. Food and Drug Administration has granted Fast Track Designation to its drug candidate CTIM-76 for the treatment of platinum-resis...
Context Plans To Report CTIM-76 Interim Phase 1a Data In June 2026; FY25 Net Loss Widens
(RTTNews) - Context Therapeutics Inc. (CNTX), a clinical-stage biopharmaceutical company, reported its full-year 2025 financial results, reflecting a wider net loss, and outlined upcoming milestones a...
Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards
VANCOUVER, British Columbia, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Equity-Insider.comNews Commentary – The FDA is moving to require just one clinical trial for new drug approvals, signaling a dramatic...
Get Context Therapeutics Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
